-
Mashup Score: 0
Atsena Therapeutics has announced that dosing has begun for the second cohort in LIGHTHOUSE, a phase 1/2 clinical trial evaluating subretinal injection of ATSN-201, a gene therapy intended to treat X-linked retinoschisis.
Source: www.retinalphysician.comCategories: General Medicine News, OphthalmologyTweet
-
Mashup Score: 26Cloaking Device: Liu, Joung Launch $100M Nvelop Therapeutics to Advance Delivery of Genetic Cargo - 1 month(s) ago
A $100-million startup is developing not one but two answers to the challenge that has long dogged the gene therapy field: How can genetic medicines best be delivered to patients safely and effectively?
Source: www.genengnews.comCategories: General Medicine News, Future of MedicineTweet
-
Mashup Score: 6Gene Therapy for Wet Age-related Macular Degeneration - 1 month(s) ago
PentaVision is an independent company dedicated to eye care professionals. More about our magazines, newsletters, conferences, education and other services at pentavisionmedia.com.
Source: www.retinalphysician.comCategories: General Medicine News, OphthalmologyTweet
-
Mashup Score: 4A look at breakthrough treatment for sickle cell anemia - 3 month(s) ago
A cutting-edge gene therapy is offering new hope in combating the painful disease that afflicts about 100,000 Americans, many of whom are Black.
Source: www.goodmorningamerica.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 4A look at breakthrough treatment for sickle cell anemia - 3 month(s) ago
A cutting-edge gene therapy is offering new hope in combating the painful disease that afflicts about 100,000 Americans, many of whom are Black.
Source: www.goodmorningamerica.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 8Peter Kaiser MD and Veeral Sheth MD MBA FACS FASRS discuss reducing injection burden and gene therapy - 3 month(s) ago
PentaVision is an independent company dedicated to eye care professionals. More about our magazines, newsletters, conferences, education and other services at pentavisionmedia.com.
Source: retinalphysician.comCategories: General Medicine News, OphthalmologyTweet
-
Mashup Score: 9CRISPR-Repaired T Cells May Treat Fatal Inflammatory Diseases - 3 month(s) ago
A novel gene therapy approach that repairs autologous T cells may offer hope to patients with familial hemophagocytic lymphohistiocytosis.
Source: www.genengnews.comCategories: General Medicine News, Future of MedicineTweet
-
Mashup Score: 138Early predictive factors of failure in autologous CAR T-cell manufacturing and/or efficacy in hematologic malignancies - 3 month(s) ago
Abstract. Chimeric antigen receptor (CAR) T-cell therapies have shown significant benefits in the treatment of hematologic malignancies, such as B-cell acute ly
Source: ashpublications.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 9CRISPR-Repaired T Cells May Treat Fatal Inflammatory Diseases - 3 month(s) ago
A novel gene therapy approach that repairs autologous T cells may offer hope to patients with familial hemophagocytic lymphohistiocytosis.
Source: www.genengnews.comCategories: General Medicine News, Future of MedicineTweet
-
Mashup Score: 9CRISPR-Repaired T Cells May Treat Fatal Inflammatory Diseases - 3 month(s) ago
A novel gene therapy approach that repairs autologous T cells may offer hope to patients with familial hemophagocytic lymphohistiocytosis.
Source: www.genengnews.comCategories: General Medicine News, Future of MedicineTweet
LIGHTHOUSE Trial for XLRS #GeneTherapy Initiates Dosing of Second Cohort: Atsena Therapeutics announced dosing has begun in a phase 1/2 clinical trial evaluating a gene therapy for X-linked retinoschisis. https://t.co/K3rIdMyb3s https://t.co/fs2mbyI1f8